Cerevance Presents at IAPRD XXIX World Congress on Parkinson’s Disease and Related Disorders
09 Mayo 2024 - 7:00AM
Cerevance, a company focused on developing precision novel
therapeutics for central nervous system (CNS) diseases, will
present an oral presentation at the upcoming International
Association of Parkinsonism and Related Disorders (IAPRD) XXIX
World Congress on Parkinson’s Disease and Related Disorders, taking
place in Lisbon, Portugal from May 19-22, 2024.
Presentation details
Title: CVN424, a Novel GPR6 Inverse Agonist
Demonstrates Efficacy in an Adjunctive Parkinson’s Disease Phase 2
Clinical TrialOverview: In a Phase 2 clinical
trial, CVN424, a novel, non-dopaminergic, GPR6 inverse agonist,
demonstrated a significant reduction in OFF time and was safe and
well tolerated with low rates of mostly mild and moderate adverse
events. Patients also reported enhanced motor functionality in
daily activities, as assessed by the UPDRS Part II. These findings
enhance the confidence in CVN424's potential to address both motor
and non-motor symptoms of Parkinson’s disease, consistent with
observations in pre-clinical models, potentially heralding a
transformative non-dopaminergic therapy.Presenter:
Karl Kieburtz, MD, MPHSession Date and Time:
Monday, May 20; 9:35 – 10:20am Session Title: PD
Therapy I
About CerevanceCerevance is focused on the
development of precision treatments for central nervous system
(CNS) disorders, including chronic neurodegenerative conditions
such as Alzheimer's disease, Parkinson's disease, frontotemporal
dementia, and amyotrophic lateral sclerosis. Utilizing a large and
growing repository of over 15,000 human brain tissue samples,
Cerevance is generating an unprecedented level of expression and
epigenetic data thereby enabling the company to identify the most
promising targets for the next generation of treatments for CNS
disorders.
The company uses its proprietary Nuclear Enriched Transcript
Sort sequencing (NETSseq) platform and advanced machine learning
techniques to uncover the gene expression profiles of select cell
types to identify novel targets that are uniquely expressed in
relevant circuits affected by diseases or are altered in disease
states. With the information obtained from its research, combined
with the expertise of its team of scientists and drug developers,
Cerevance is advancing multiple therapeutics through clinical
development, with CVN424, CVN766, and CVN293 being the furthest
along in the pipeline. CVN424 is a first-in-class non-dopamine
therapy that shows promise in improving both motor and non-motor
symptoms of Parkinson's disease and may also have disease-delaying
effects. CVN766 is a potent and highly selective antagonist of the
orexin 1 receptor which may benefit various psychiatric conditions
including schizophrenia, anxiety/panic, binge eating/obesity,
substance use disorder, and Prader-Willi Syndrome. CVN293 is a
novel blocker of potassium efflux in glia, regulating the
inflammasome in individuals living with neurodegenerative
diseases.
Cerevance’s robust pipeline aims to transform the lives of
patients affected by CNS diseases.
Contacts
Cerevance: Johnna Simoes, ir@cerevance.com
Media: Andrew Mielach,
amielach@lifescicomms.com, +1-646-876-5868